Created a new medication for psoriasis - Tildraqizumab
Last reviewed: 23.04.2024
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
The newest antipsoriatic agent Tildraqizumab has already successfully passed the first clinical trials: it is established that the drug is perfectly tolerated by patients who suffer from a severe and moderate form of psoriasis.
" Psoriasis is a complex pathology, which is almost impossible to cure completely. For fifteen years we have been studying any possibilities for treating this disease and have made some progress: according to the latest tests, the new, developed by us drug successfully blocks a key link in the chain of psoriasis development, eliminating the painful signs of the disease, "says Professor Alex Kimbell, doctor-dermatologist at Harvard University and Med-Center Bet-Israel.
The newest drug Tildrakizumab is a combination of selectively reacting monoclonal antibodies, which belong to the category of biologics. The drug is similar to molecules produced in the body to resist the disease.
Tildrakizumab refers to medications - selective inhibitors of interleukin-23.
Clinical experiments on the new drug were funded by the pharmaceutical association Merck.
Nearly two thousand patients with various forms of psoriasis were involved in the studies, which were treated in different clinical centers in several countries around the world.
The volunteer volunteers participating in the experiment had more than 30% of the psoriasis of the trunk surface. They were randomly divided into three groups. Patients in the first group received intravenous injections of the new drug in an amount of 200 mg. The dosage for the second group was 100 mg. The third group of patients received the drug "placebo".
After 12 weeks of therapy, 65% of patients showed a persistent improvement in their condition: they almost got rid of the leading symptoms of psoriasis. In the group taking participants "placebo," improvement was recorded only in 10% of cases.
"Undoubtedly, we still have a lot of work to improve the new drug. Our task is to make the medicine extremely effective with minimal danger of influence on the work of other organs and systems. The results of the study indicate that it was unreasonable to stop the experiment after twelve weeks: it is too short a period of time in order to obtain correct and truthful results in terms of the degree of cure for psoriasis, "the study authors note.
Previously, medical specialists used mainly first-generation drugs for the treatment of psoriasis, which appeared on the pharmaceutical market about fifteen years ago. These drugs allowed to qualitatively improve the indices and the frequency of remissions in patients with severe forms of the disease.
Medication Tildraqizumab, recently developed by scientists, should improve the quality of treatment of psoriasis.
The results of the latest research in this area can be found on the pages of the periodic scientific journal The Lancet.
[